Cancer metabolism within tumor microenvironments
Sho Aki1, Ryuichi Nakahara1, Keisuke Maeda2
1Division of Nutriomics and Oncology, RCAST, The University of Tokyo, 4-6-1 Komaba, Meguro-ku, Tokyo 153-8904, Japan; Department of Chemistry and Biotechnology, Graduate School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8654, Japan.
Biochimica Et Biophysica Acta. General Subjects
|February 22, 2023
Summary
Tumor microenvironments drive cancer malignancy and drug resistance through metabolic alterations. Targeting cell-cell and organelle-organelle metabolic interactions offers novel therapeutic strategies for improved cancer treatment outcomes.
Area of Science:
- Oncology
- Cancer Biology
- Metabolic Research
Background:
- Tumor microenvironments (TMEs) significantly influence cancer heterogeneity and malignancy.
- Factors like hypoxia, nutrient deprivation, and acidic pH promote cancer progression, invasion, and metastasis.
- Cancer cell adaptation to TMEs leads to immune evasion, drug resistance, and recurrence, impacting patient prognosis.
Purpose of the Study:
- To review metabolic alterations within TMEs.
- To explore cell-to-cell and organelle-to-organelle metabolic interactions in cancer.
- To provide novel insights into cancer therapy targeting these metabolic interactions.
Main Methods:
- Literature review of metabolic alterations in TMEs.
- Analysis of cell-cell metabolic crosstalk in cancer.
- Examination of organelle-organelle interactions and their role in metabolic adaptation.
Main Results:
- TMEs induce genetic, epigenetic, and metabolic changes in cancer cells.
- Cell-cell metabolic interactions contribute to cancer malignancy.
- Organelle-organelle interactions are critical for metabolic adaptation to TMEs and represent potential therapeutic targets.
Conclusions:
- Metabolic reprogramming within TMEs is a key driver of cancer malignancy and therapeutic resistance.
- Targeting metabolic interactions, including those between organelles, presents a promising avenue for novel cancer therapies.
- Understanding these complex metabolic networks is crucial for developing effective treatments against aggressive cancers.
Related Concept Videos
02:17The Tumor Microenvironment
6.7K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.7K
02:53Adaptive Mechanisms in Cancer Cells
5.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K
02:30Metastasis
5.6K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.6K
02:40Cancer Stem Cells and Tumor Maintenance
5.0K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K